Media stories about Eyegate Pharmaceuticals (NASDAQ:EYEG) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eyegate Pharmaceuticals earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned media stories about the specialty pharmaceutical company an impact score of 45.5835509798409 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
A number of analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target (down previously from $5.00) on shares of Eyegate Pharmaceuticals in a research report on Tuesday, February 6th. ValuEngine raised Eyegate Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd.
Eyegate Pharmaceuticals (EYEG) traded down $0.01 during midday trading on Wednesday, hitting $0.68. The company had a trading volume of 96,100 shares, compared to its average volume of 405,640. Eyegate Pharmaceuticals has a fifty-two week low of $0.50 and a fifty-two week high of $3.90. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 0.01. The firm has a market cap of $11.54 and a PE ratio of -0.58.
Eyegate Pharmaceuticals (NASDAQ:EYEG) last posted its quarterly earnings data on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.24) earnings per share for the quarter, hitting the consensus estimate of ($0.24). Eyegate Pharmaceuticals had a negative return on equity of 1,494.75% and a negative net margin of 2,480.28%. sell-side analysts predict that Eyegate Pharmaceuticals will post -1.01 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/14/eyegate-pharmaceuticals-eyeg-getting-somewhat-favorable-media-coverage-analysis-shows.html.
About Eyegate Pharmaceuticals
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.